The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Two new drugs will soon be available to target little-known forms of high cholesterol, which are driven by our genes and ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart ...

Monash University and Monash Health are collaborating on projects that aim to develop the first effective drug for two types of high cholesterol that until now have had no effective treatment. The ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...